You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神州細胞(688520.SH)2021年度預虧8.5億-8.8億元
格隆匯 01-28 21:07

格隆匯1月28日丨神州細胞(688520.SH)公佈,公司預計2021年度實現歸屬於母公司所有者的淨虧損約8.5億元到8.8億元,與上年同期相比,將增加虧損約1.375億元到1.675億元。

公司預計2021年度歸屬於母公司所有者的扣除非經常性損益後的淨虧損約8.693億元到8.993億元,與上年同期相比,將增加虧損約1.014億元到1.314億元。

業績變化的主要原因:()報吿期內,公司預計實現營業收入約1.2億元到1.4億元,系因司自主研發的首個產品安佳因®(SCT800組人凝血因子VIII)20217獲批上市,並開始持續產生銷售收入但由於公司在研產品眾多、且多個產品在開展針對不同適應症的 II/III 期臨牀研究相關研發費用尤其是臨牀研究費用支出較大,從而導致公司報吿期內研發費用增幅較大

(二)報吿期內,隨着安佳因®的上市,公司市場銷售團隊進一步擴充應的人員薪酬推廣費等市場銷售費用也同步增加。

(三)報吿期公司收到的政府補助減少等因素影響導致非經常性損益上年同期減少

綜上公司 2021 年度持續出現歸屬於母公司所有者的淨利潤為負的情況

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account